Cargando…

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression

A 56-year-old male was diagnosed with right lung upper lobe squamous cancer with right hilar and mediastinum lymph node metastasis. After four cycles of neoadjuvant immunochemotherapy, reexamination by computed tomography showed progressive disease of the primary lesion. Then, the patient underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Wenxiao, Zhu, Hui, Gao, Qianqian, Sun, Jian, Tan, Fujian, Liu, Qun, Guo, Hongbo, Yu, Jinming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925896/ https://www.ncbi.nlm.nih.gov/pubmed/33679783 http://dx.doi.org/10.3389/fimmu.2021.633534

Ejemplares similares

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
por: Jia, Wenxiao, et al.
Publicado: (2019)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
por: Koch, Agnes, et al.
Publicado: (2022)

Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa
por: Gao, Lei, et al.
Publicado: (2022)

Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
por: Cai, Wenhan, et al.
Publicado: (2022)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
por: Jia, Wenxiao, et al.
Publicado: (2023)

Multiple Brain Pseudoprogression in a Patient With NSCLC Treated With Pembrolizumab
por: Moliner, Laura, et al.
Publicado: (2020)

A novel immune-nutritional score predicts response to neoadjuvant immunochemotherapy after minimally invasive esophagectomy for esophageal squamous cell carcinoma
por: Feng, Jifeng, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease
por: Roatt, Bruno Mendes, et al.
Publicado: (2014)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

The usefulness of pretreatment controlling nutritional status score for predicting recurrence in patients with esophageal squamous cell carcinoma undergoing neoadjuvant immunochemotherapy: A real-world study
por: Feng, Jifeng, et al.
Publicado: (2022)

Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study
por: Pan, Hanbo, et al.
Publicado: (2023)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
por: Li, Yan, et al.
Publicado: (2021)

Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
por: Cui, Yingpu, et al.
Publicado: (2022)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule
por: da Silva, Danielle A. M., et al.
Publicado: (2020)

Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature
por: Sheng, Jin, et al.
Publicado: (2023)

Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
por: Zeng, Jiao, et al.
Publicado: (2023)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Cold stimuli, hot topic: An updated review on the biological activity of menthol in relation to inflammation
por: Cheng, Haojin, et al.
Publicado: (2022)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy
por: Zhu, Yuan-Xue, et al.
Publicado: (2022)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Pushing the limits of immune-related response: a case of “extreme pseudoprogression”
por: Wong, Alvin S., et al.
Publicado: (2018)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs
por: Liu, Dongze, et al.
Publicado: (2022)

Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023)

Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
por: Zhai, Wen-Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0u283ub5dmf6cqttbgk99lvh7h